Cancer Genetics: Mechanisms, Mutations, and Clinical Implications

Cancer Genetics

Introduction

Cancer genetics explores the molecular and cellular mechanisms underlying the development and progression of cancer. It focuses on the genetic changes that drive neoplastic transformation, genomic instability, and the clinical implications for diagnosis and therapy.

Objectives in Cancer Genetics

Key Learning Goals

• Defend the two-hit hypothesis: Understand the genetic basis of tumor suppressor gene inactivation.

• Determine types of genomic instability: Identify mechanisms and consequences of chromosomal and microsatellite instability in cancer cells.

• List six characteristics of tumor cells: Recognize the hallmarks that confer malignancy.

• Describe the role of cell cycle checkpoints: Explain how checkpoints prevent genomic instability and tumorigenesis.

Neoplasia: Definition and Types

Neoplasia and Tumor Classification

Neoplasia refers to uncontrolled cellular proliferation resulting in a mass or tumor (neoplasm). The process involves an imbalance between cell growth and programmed cell death (apoptosis).

• Malignant tumors: Exhibit uncontrolled growth, invade neighboring tissues, and can spread (metastasize) to distant sites.

• Benign tumors: Do not invade or metastasize; remain localized.

Stages of Tumor Progression

• Normal epithelium: Cells are organized and non-proliferative.

• Proliferation: Cells begin to divide abnormally.

• Local invasion: Tumor cells invade adjacent tissues.

• Lymph node invasion: Tumor cells spread to lymphatic system.

• Distant metastases: Tumor cells colonize distant organs (e.g., liver, lungs).

Hallmarks of Cancer

Six Essential Capabilities of Malignant Tumors

• Self-sufficiency in growth signals: Cancer cells generate their own signals to proliferate.

• Insensitivity to anti-growth signals: Ignore signals that normally inhibit cell division.

• Evading apoptosis: Avoid programmed cell death mechanisms.

• Limitless replicative potential: Maintain telomere length, allowing indefinite division.

• Sustained angiogenesis: Stimulate new blood vessel formation to supply nutrients.

• Tissue invasion and metastasis: Invade surrounding tissues and spread to distant sites.

Genomic Instability in Cancer

Types of Genomic Instability

• Chromosomal instability (CIN): Characterized by abnormal chromosome number and structure, including deletions, amplifications, translocations, and complex rearrangements.

• Microsatellite instability (MSI): Involves errors in short repetitive DNA sequences due to defective mismatch repair (MMR) genes, leading to increased mutation rates.

Role of Cell Cycle Checkpoints

• Checkpoints: Ensure accurate DNA replication and chromosome segregation; prevent propagation of damaged DNA.

• Key proteins: Cyclins, cyclin-dependent kinases (CDKs), and tumor suppressors (e.g., p53, Rb).

• Loss of checkpoint function: Leads to accumulation of mutations and genomic instability.

Genetic Mutations in Cancer

Driver vs. Passenger Mutations

• Driver mutations: Directly contribute to cancer development and progression.

• Passenger mutations: Occur randomly and do not affect tumor behavior.

Types of Genetic Alterations

• Point mutations: Single nucleotide changes that can activate oncogenes or inactivate tumor suppressor genes.

• Gene amplification: Multiple copies of oncogenes increase their expression.

• Chromosomal rearrangements: Translocations, deletions, and duplications disrupt gene function.

Oncogenes and Tumor Suppressor Genes

Oncogenes

• Proto-oncogenes: Normal genes that regulate cell growth and differentiation.

• Oncogenes: Mutated or overexpressed proto-oncogenes with gain-of-function mutations, driving uncontrolled proliferation.

• Activation mechanisms: Point mutations, gene amplification, chromosomal translocations.

Tumor Suppressor Genes

• Function: Inhibit cell growth, promote DNA repair, and trigger apoptosis.

• Loss-of-function mutations: Lead to unchecked cell division and tumorigenesis.

• Examples: TP53, RB1, APC, BRCA1/2.

The Two-Hit Hypothesis

Knudson's Hypothesis

The two-hit hypothesis explains the genetic basis of hereditary cancer syndromes. It states that both alleles of a tumor suppressor gene must be inactivated for cancer to develop.

• First hit: Germline (inherited) mutation in one allele.

• Second hit: Somatic mutation or loss of heterozygosity (LOH) in the other allele.

• Example: Retinoblastoma (RB1 gene).

Hereditary Cancer Syndromes

Common Syndromes and Associated Genes

Syndrome	Gene	Chromosome
Retinoblastoma	RB1	13q14
Familial adenomatous polyposis	APC	5q21
Lynch syndrome (HNPCC)	MSH2, MLH1, MSH6, MLH3, PMS1, PMS2	2p22, 3p21, 2p16, 14q24, 2q31, 7p22
Breast and ovarian cancer	BRCA1, BRCA2	17q21, 13q12
Li-Fraumeni syndrome	TP53	17p13
Neurofibromatosis type 1	NF1	17q11
Multiple endocrine neoplasia 1	MEN1	11q13
Multiple endocrine neoplasia 2	RET	10q11
Familial melanoma	CDKN2A	9p21

Epigenetic Changes in Cancer

DNA Methylation and Gene Silencing

• Global hypomethylation: Reduces overall DNA methylation, leading to genomic instability.

• Promoter hypermethylation: Silences tumor suppressor genes (e.g., MLH1), contributing to cancer progression.

Cancer Genomics and Therapy

Personalized Medicine

• Cancer genomics: Guides diagnosis, classification, prognosis, and targeted therapy.

• Targeted therapy: Drugs designed to block specific driver mutations or pathways (e.g., tyrosine kinase inhibitors, monoclonal antibodies).

Examples of Targeted Therapies

Driver Gene/Mutation	Approved Therapy
Amplified HER2	Trastuzumab (HER2 monoclonal antibody)
Activated EGFR	Tyrosine kinase inhibitors (e.g., gefitinib, erlotinib)
Translocated ALK	ALK inhibitors (e.g., crizotinib)
Activated BRAF	BRAF inhibitors (e.g., vemurafenib)

Prevalence of Key Mutations in Cancer Types

Mutation	Cancer Type	Prevalence (%)
EGFR overexpression	Colorectal	77
EGFR overexpression	Pancreatic	30-50
EGFR overexpression	Lung	40-80
EGFR mutation	NSCLC	10
RAS mutation	Pancreatic	90
BRAF mutation	Melanoma	70
BRAF mutation	Papillary thyroid	50

Summary

Cancer genetics integrates molecular biology, genomics, and clinical medicine to understand the origins and progression of cancer. Key concepts include neoplasia, genomic instability, oncogenes, tumor suppressor genes, hereditary syndromes, and the application of genomics to personalized therapy.

Additional info: Some content was inferred and expanded for clarity and completeness, including the structure of hereditary syndromes and targeted therapies.